Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 13/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 5/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878373 | 0.96 | PPARA (0.54) | PPARAPOLBL3MBTL1PPARDPPARG | |
| SCHEMBL4875329 | 0.94 | CNR1 (0.51) | PPARAPOLBL3MBTL1PPARDPPARG | |
| SCHEMBL4874131 | 0.93 | PPARA (0.55) | PPARAPOLBL3MBTL1PPARDPPARG | |
| SCHEMBL4877901 | 0.93 | PPARA (0.55) | PPARAPOLBL3MBTL1PPARDPPARG | |
| SCHEMBL4876902 | 0.93 | PPARA (0.46) | PPARAPOLBL3MBTL1PPARDMAPT | |
| SCHEMBL4879685 | 0.92 | PPARA (0.56) | PPARAPOLBL3MBTL1PPARDPPARG | |
| SCHEMBL4872840 | 0.92 | PPARA (0.58) | PPARAPPARDPPARGALDH1A1 | |
| SCHEMBL14197489 | 0.90 | CNR1 (0.51) | PPARAPOLBL3MBTL1PPARDPPARG | |
| SCHEMBL4874680 | 0.88 | PPARA (0.49) | PPARAPOLBL3MBTL1PPARDPPARG | |
| SCHEMBL4867536 | 0.88 | PPARA (0.58) | PPARAPPARDPPARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633747-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS PPAR-A ACTIVATORS | Pfizer Products Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| US-6987118-B2 | Tetrahydroisoquinoline derivatives as PPAR-alpha activators | PFIZER INC. (US) | 2006-01-17 | — | — | US | claimed |
| US-20040248934-A1 | Tetrahydroisoquinoline derivatives as PPAR-alpha activators | PFIZER INC. | 2004-12-09 | — | — | US | claimed |
| WO-2004103997-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS PPAR-α ACTIVATORS | PFIZER PRODUCTS INC. (US) | 2004-12-02 | — | — | WO | claimed |
| US-20080096916-A1 | Drugs And Prodrugs Useful The Treatment Of Energy Balance In Ruminants | PFIZER INC. (US) | 2008-04-24 | — | — | US | disclosed |
| EP-1824484-A1 | DRUGS AND PRODRUGS USEFUL FOR THE TREATMENT OF ENERGY BALANCE IN RUMINANTS | Pfizer Products Incorporated (US) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006054166-A1 | DRUGS AND PRODRUGS USEFUL FOR THE TREATMENT OF ENERGY BALANCE IN RUMINANTS | PFIZER PRODUCTS INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| EP-1633747-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS PPAR-A ACTIVATORS | Pfizer Products Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-6987118-B2 | Tetrahydroisoquinoline derivatives as PPAR-alpha activators | PFIZER INC. (US) | 2006-01-17 | — | — | US | disclosed |
| US-20040248934-A1 | Tetrahydroisoquinoline derivatives as PPAR-alpha activators | PFIZER INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004103997-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS PPAR-α ACTIVATORS | PFIZER PRODUCTS INC. (US) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248934-A1 | Tetrahydroisoquinoline derivatives as PPAR-alpha activators | PPARA, PPARG, PPARD | PPARA 1/4885POLB 2223/4885L3MBTL1 2871/4885 |
| US-20080096916-A1 | Drugs And Prodrugs Useful The Treatment Of Energy Balance In Ruminants | ALPP, PIGS, GYS2 | PPARA 614/4885POLB 2310/4885L3MBTL1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.